WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H407895
CAS#: 1832671-96-1
Description: Y06036 is a potent BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Y06036 bounds to the BRD4(1) bromodomain with Kd values of 82 nM. Y06036 also exhibited high selectivity over other non-BET subfamily members. Y06036 potently inhibited cell growth, colony formation, and the expression of AR, AR regulated genes, and MYC in prostate cancer cell lines. Y06036 also demonstrated therapeutic effects in a C4-2B CRPC xenograft tumor model in mice.
Hodoodo Cat#: H407895
Name: Y06036
CAS#: 1832671-96-1
Chemical Formula: C16H15BrN2O5S
Exact Mass: 425.99
Molecular Weight: 427.269
Elemental Analysis: C, 44.98; H, 3.54; Br, 18.70; N, 6.56; O, 18.72; S, 7.50
Synonym: Y06036; Y-06036; Y 06036.
IUPAC/Chemical Name: 5-Bromo-2-methoxy-N-(6-methoxy-3-methylbenzo[d]-isoxazol-5-yl)benzenesulfonamide
InChi Key: KVGNGFGTOSOVPB-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H15BrN2O5S/c1-9-11-7-12(15(23-3)8-14(11)24-18-9)19-25(20,21)16-6-10(17)4-5-13(16)22-2/h4-8,19H,1-3H3
SMILES Code: O=S(C1=CC(Br)=CC=C1OC)(NC2=C(OC)C=C(ON=C3C)C3=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 427.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Zhang M, Zhang Y, Song M, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Zou
L, Wu X, Wu C, Dong B, Xue W, Zhou Y, Chen H, Wu D, Ding K, Xu Y. Structure-Based
Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and
Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate
Cancer (CRPC). J Med Chem. 2018 Mar 22. doi: 10.1021/acs.jmedchem.8b00103. [Epub
ahead of print] PubMed PMID: 29566488.